DK1140170T3 - Antistoffragmenter til topisk behandling af öjensygdomme - Google Patents

Antistoffragmenter til topisk behandling af öjensygdomme

Info

Publication number
DK1140170T3
DK1140170T3 DK99966798T DK99966798T DK1140170T3 DK 1140170 T3 DK1140170 T3 DK 1140170T3 DK 99966798 T DK99966798 T DK 99966798T DK 99966798 T DK99966798 T DK 99966798T DK 1140170 T3 DK1140170 T3 DK 1140170T3
Authority
DK
Denmark
Prior art keywords
antibody fragments
eye diseases
topical treatment
sub
disorder
Prior art date
Application number
DK99966798T
Other languages
Danish (da)
English (en)
Inventor
Douglas John Coster
Keryn Anne Williams
Michael Alexander Thiel
Heddy Zola
Original Assignee
Univ Southern Australia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPP8033A external-priority patent/AUPP803399A0/en
Priority claimed from AUPQ3305A external-priority patent/AUPQ330599A0/en
Application filed by Univ Southern Australia filed Critical Univ Southern Australia
Application granted granted Critical
Publication of DK1140170T3 publication Critical patent/DK1140170T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
DK99966798T 1999-01-05 1999-12-24 Antistoffragmenter til topisk behandling af öjensygdomme DK1140170T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP8033A AUPP803399A0 (en) 1999-01-05 1999-01-05 Novel therapeutic and diagnostic agent for ocular disorders
AUPQ3305A AUPQ330599A0 (en) 1999-10-07 1999-10-07 Novel agents for treatment and diagnosis of ocular disorders

Publications (1)

Publication Number Publication Date
DK1140170T3 true DK1140170T3 (da) 2006-10-23

Family

ID=25645965

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99966798T DK1140170T3 (da) 1999-01-05 1999-12-24 Antistoffragmenter til topisk behandling af öjensygdomme

Country Status (9)

Country Link
US (1) US6773916B1 (ja)
EP (1) EP1140170B1 (ja)
JP (3) JP5483789B2 (ja)
AT (1) ATE330631T1 (ja)
CA (1) CA2348488C (ja)
DE (1) DE69932084T2 (ja)
DK (1) DK1140170T3 (ja)
NZ (1) NZ511219A (ja)
WO (1) WO2000040262A1 (ja)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670321B1 (en) * 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
WO2000040262A1 (en) * 1999-01-05 2000-07-13 The Flinders University Of South Australia Novel agents and methods for treatment and diagnosis of ocular disorders
CA2387889A1 (en) * 1999-10-22 2001-05-03 Biogen, Inc. Use of a cd40:cd154 binding interruptor to treat immunological complications of the eye
EP1363643A2 (en) 2000-12-22 2003-11-26 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
JP2002208294A (ja) * 2001-01-12 2002-07-26 Toshiba Corp リダンダンシーシステムを有する半導体記憶装置
CA2445269A1 (en) * 2001-05-03 2002-11-14 Novartis Ag Anti-ige antibody to treat ocular allergies
JP4838968B2 (ja) * 2001-09-28 2011-12-14 参天製薬株式会社 薬物−ポリエチレングリコール結合体を含有する眼組織内注入剤
EP2267032A3 (en) * 2002-11-08 2011-11-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
WO2004041865A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Stabilized single domain antibodies
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
PT1682537E (pt) 2003-11-05 2012-06-20 Sarcode Bioscience Inc Moduladores de adesão celular
US20050197310A1 (en) * 2004-01-30 2005-09-08 Orna Mor Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
DK1881823T3 (en) 2005-05-17 2015-03-02 Sarcode Bioscience Inc COMPOSITION AND PROCEDURES FOR TREATMENT OF EYE DISORDERS
US9198981B2 (en) * 2006-02-01 2015-12-01 The University Of Kentucky Modulation of angiogenesis
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
US20070218007A1 (en) * 2006-03-17 2007-09-20 Allergan, Inc. Ophthalmic visualization compositions and methods of using same
US7918814B2 (en) * 2006-05-02 2011-04-05 Georgia Tech Research Corporation Method for drug delivery to ocular tissue using microneedle
US8197435B2 (en) * 2006-05-02 2012-06-12 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
US20080138334A1 (en) 2006-05-31 2008-06-12 Sabbadini Roger A Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same
US9274129B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
US9274130B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Prevention and treatment of pain using antibodies to lysophosphatidic acid
AU2007272224B2 (en) 2006-07-10 2013-05-02 Novartis Ag scFv antibodies which pass epithelial and/or endothelial layers
US20080031903A1 (en) * 2006-07-27 2008-02-07 Andrea Gambotto Method of treating ocular infections
KR101581279B1 (ko) 2006-10-27 2015-12-31 엘파스, 인크. 스핑고신-1-포스페이트 결합을 위한 조성물 및 방법
CA2705859A1 (en) * 2007-10-15 2009-04-23 John P. Stokes Convergent well irradiating plaque for choroidal melanoma
ES2830024T3 (es) 2007-10-19 2021-06-02 Novartis Ag Composiciones y métodos para el tratamiento del edema macular
WO2009128933A1 (en) * 2008-04-15 2009-10-22 Sarcode Corporation Aerosolized lfa-1 antagonists for use in localized treatment of immune related disorders
WO2009128932A1 (en) * 2008-04-15 2009-10-22 Sarcode Corporation Delivery of lfa-1 antagonists to the gastrointestinal system
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
ES2763703T3 (es) * 2008-04-15 2020-05-29 Sarcode Bioscience Inc Antagonistas de LFA-1 tópicos utilizados en el tratamiento localizado de trastornos inmunes
US7772006B2 (en) * 2008-08-21 2010-08-10 Paul Tornambe Agent detection and/or quantitation in a biological fluid
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
WO2010129033A2 (en) * 2009-04-29 2010-11-11 Calmune Corporation Modified antibodies for passive immunotherapy
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
US8735648B2 (en) 2010-02-08 2014-05-27 Cornell University Model system of Acanthamoeba keratitis syndrome and method for selecting a treatment thereof
WO2013113820A1 (en) * 2012-02-02 2013-08-08 Esbatech - A Novartis Company Llc Antibody-containing sustained-release formulation for ocular administration
CN110922393A (zh) 2012-07-25 2020-03-27 诺华股份有限公司 Lfa-1抑制剂及其多晶型物
BR112015010566A2 (pt) 2012-11-08 2017-07-11 Clearside Biomedical Inc métodos e dispositivos para o tratamento de doenças oculares em indivíduos humanos
AU2014215639B2 (en) * 2013-01-25 2017-03-23 Thymon, Llc Compositions for selective reduction of circulating bioactive soluble TNF and methods for treating TNF-mediated disease
PL2991479T3 (pl) * 2013-03-14 2018-04-30 Université Jean-Monnet Urządzenie medyczne do przechowywania rogówki
WO2014179698A2 (en) 2013-05-03 2014-11-06 Clearside Biomedical, Inc. Apparatus and methods for ocular injection
US10188550B2 (en) 2013-06-03 2019-01-29 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
WO2015095772A2 (en) 2013-12-20 2015-06-25 Emory University Formulations and methods for targeted ocular delivery of therapeutic agents
RU2710491C2 (ru) 2014-06-20 2019-12-26 Клиасайд Байомедикал, Инк. Устройство для инъекции лекарственного средства в глазную ткань и способ инъекции лекарственного средства в глазную ткань
KR20170043655A (ko) * 2014-09-09 2017-04-21 아르투로 솔리스 헤레라 멜라닌 및 멜라닌 유사체, 전구체, 및 유도체로 안과 질병, 질환, 및 증상의 치료 및 예방을 위한 방법
USD750223S1 (en) 2014-10-14 2016-02-23 Clearside Biomedical, Inc. Medical injector for ocular injection
AU2016209550A1 (en) * 2015-01-20 2017-08-03 Veloce Biopharma Llc Novel iodophor composition and methods of use
EP3173098A1 (en) 2015-11-27 2017-05-31 Assistance Publique-Hopitaux De Paris Immunostimulatory compositions
US10390901B2 (en) 2016-02-10 2019-08-27 Clearside Biomedical, Inc. Ocular injection kit, packaging, and methods of use
US10443032B2 (en) * 2016-04-19 2019-10-15 The Government Of The United States, As Represented By The Secretary Of The Army Device and method for isolation of corneal endothelial cells
WO2017192565A1 (en) 2016-05-02 2017-11-09 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
IL264764B2 (en) 2016-08-12 2024-02-01 Clearside Biomedical Inc Devices and methods for adjusting the insertion depth of a drug administration needle
CN109706238B (zh) 2017-10-26 2023-04-07 珠海岐微生物科技有限公司 一种老年性黄斑病变的检测与治疗方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS568324A (en) * 1979-07-04 1981-01-28 Mochida Pharmaceut Co Ltd Infectious disease remedy for external and ophthalmologic application
US5616122A (en) 1986-11-04 1997-04-01 Baylor College Of Medicine Methods and compositions for preventing secondary cataracts
JPH07121879B2 (ja) * 1986-11-14 1995-12-25 富士レビオ株式会社 点眼用免疫グロブリン製剤
IL97075A0 (en) * 1990-02-14 1992-03-29 Alcon Lab Inc Topical pharmaceutical composition containing an alkyl saccharide
JP3679112B2 (ja) * 1991-10-04 2005-08-03 アメリカ合衆国 細胞接着分子の遮断による眼の炎症の治療
EP0627932B1 (en) * 1992-11-04 2002-05-08 City Of Hope Antibody construct
WO1994014475A1 (en) * 1992-12-21 1994-07-07 Tanox Biosystems, Inc. ALLERGEN-SPECIFIC IgA MONOCLONAL ANTIBODIES AND RELATED PRODUCTS FOR ALLERGY TREATMENT
US5670132A (en) * 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
AU6763496A (en) * 1995-08-07 1997-03-05 Schering Corporation Treatment of ocular inflammatory conditions with interleukin-10
CA2253942A1 (en) 1996-05-10 1997-11-20 Biogen, Inc. Common gamma chain blocking agents
JPH1180024A (ja) * 1997-09-12 1999-03-23 Toagosei Co Ltd 角膜血管新生阻害剤
TWI259837B (en) * 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
WO2000040262A1 (en) * 1999-01-05 2000-07-13 The Flinders University Of South Australia Novel agents and methods for treatment and diagnosis of ocular disorders

Also Published As

Publication number Publication date
EP1140170A4 (en) 2002-04-10
DE69932084T2 (de) 2007-06-28
EP1140170A1 (en) 2001-10-10
DE69932084D1 (de) 2006-08-03
JP2013256541A (ja) 2013-12-26
CA2348488A1 (en) 2000-07-13
EP1140170B1 (en) 2006-06-21
JP5703039B2 (ja) 2015-04-15
NZ511219A (en) 2003-05-30
US6773916B1 (en) 2004-08-10
WO2000040262A1 (en) 2000-07-13
ATE330631T1 (de) 2006-07-15
JP2002534394A (ja) 2002-10-15
JP5483789B2 (ja) 2014-05-07
CA2348488C (en) 2011-03-01
JP2011084578A (ja) 2011-04-28

Similar Documents

Publication Publication Date Title
DK1140170T3 (da) Antistoffragmenter til topisk behandling af öjensygdomme
BRPI0413489A (pt) composições polipeptìdicas de ligação a cd20
CY1118429T1 (el) Αντισωμα συνδεσης αλφα4βητα7 ιντεγκρινης και η χρηση αυτου εις τη θεραπευτικη αγωγη της φλεγμονωδους νοσου του εντερου
DK1624892T3 (da) Terapeutisk anvendelse af anti-CSI-antistoffer
KR101155294B1 (ko) 면역특이적으로 ＢＬｙＳ에 결합하는 항체
BRPI0418695A (pt) uso terapêutico de anticorpos anti-cs1
BRPI0412245A (pt) anticorpos de rg1 e usos destes
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
ES2120416T3 (es) Inhibidores del crecimiento tumoral derivados de tejidos, metodos de preparacion y usos de dichos inhibidores.
ATE470676T1 (de) Anti-vegf-2 antikörper
UY28170A1 (es) Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes.
EA200101064A1 (ru) Лечение раковых заболеваний путем комбинированного введения доцетаксела с рекомбинантными гуманизированными моноклональными анти-her2 антителами
EA200602015A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
CY1109817T1 (el) Ολιγο-βητα-(1,3)-γλυκανη και μονοκλωνικα αντισωματα εναντιον καρκινου
BR0212907A (pt) Métodos para tratamento ou prevenção de inflamação vascular usando inibidor(es) da absorção de esteróis
EA200401081A1 (ru) Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro
BR0210648A (pt) Variante de uma molécula imunointerativa, anticorpo monoclonal, forma disimunizada de anticorpo monoclonal 3b6, método para a geração de um anticorpo monoclonal desimunizado, molécula de anticorpo desimunizada, anticorpo desimunizado, anticorpo monoclonal de murino variante 3b6 desimunizado, variante de um anticorpo monoclonal de murino 3b6 desimunizado para uso em humanos, método para a detecção de um coágulo sanguìneo em um paciente humano, método para a detecção de um coágulo sanguìneo ou de um seu fragmento de ligação a antìgeno, método para a facilitação da dissolução ou da remoção de um coágulo sanguìneo em um humano, uso de um anticorpo monoclonal derivado de murino variante, e, conjugado
CL2023000099A1 (es) Tratamiento de enfermedades inflamatorias con anticuerpos anti-factor tisular
DK1411962T3 (da) Terapi for pancreacancer med monoklonalt stof
CY1115003T1 (el) Θεραπευτικη χρηση των αντισωματων αντι-cs1
NO943653L (no) Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon
EA202192865A1 (ru) Лечение головной боли с использованием антител к cgrp
WO2003097082A3 (en) Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
DE69829995D1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
BR9910589A (pt) Anticorpo humanizado, processo para produzir anticorpo humanizado vtm1-1, composição farmacêutica, e, processo para tratar um paciente sofrendo ou em risco dos efeitos tóxicos de uma verotoxina, e, linhagem de célula